Mike Blank

Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA.

Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA.

Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA.

Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA.